NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NYSE · Medical Devices · USD

Penumbra, Inc. (PEN) Stock Analysis

Penumbra, Inc. (PEN) is a Medical Devices stock listed on NYSE and quoted in US Dollar.

PEN

$322.17

+$1.03 (+0.32%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare PEN with… →

PEN Key Statistics

As of Sep 4, 2026
Trading
Open
$321.00
Previous Close
$321.14
Day's Range
321.00–322.72
52-Week Range
221.26–362.41
Volume
174.10K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.70
Valuation
Market Cap
$12.69B
P/E Ratio
78.77
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
52.54
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
3.62
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
8.43
EPS (ttm)Profit attributable to each share over the last twelve months.
4.09
Financials (FY)
Revenue (FY)
$1.40B+17.50%
Net Income (FY)
$177.69M+1168.11%
Profit marginThe share of revenue left as profit after all costs and taxes.
10.67%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
39.39M
1-Year Return
+15.18%
Dividend and dates
Earnings Date
November 4, 2026estimated
Avg Volume
347.67K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

PEN Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+3.62%
2025+30.92%
2024−5.59%
2023+13.07%
2022−22.57%
2021+64.18%
2020+6.53%
2019+34.43%
2018+29.86%
2017+47.49%
2016 (partial year)−4.86%

As of September 4, 2026.

PEN Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$1.40B$177.69M12.7%
2024$1.19B$14.01M1.2%
2023$1.06B$90.95M8.6%
2022$847.13M−$2.00M−0.2%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$1.40B$942.44M$189.25M$177.69M12.7%
2024$1.19B$755.00M$86.22M$14.01M1.2%
2023$1.06B$682.64M$91.77M$90.95M8.6%
2022$847.13M$535.21M$6.08M−$2.00M−0.2%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

PEN Valuation vs Medical Devices Median

Median of 151 stocks
MetricPENMedical Devices medianvs median
P/E78.7726.80194% above
P/S ratio8.432.98183% above
Profit margin10.67%−1.69%12.4 pts above

Medians across 151 Medical Devices stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 7 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Penumbra, Inc. (PEN) at $12.69B. It is classified in the Medical Devices industry, within the Healthcare sector. Headcount on file is 4,700.

Over the past 52 weeks the price has ranged from $221.26 to $362.41. PEN last closed at $322.17 on September 4, 2026. That is +$1.03 (+0.32%) against the previous close. The latest close sits 45.61% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $1.40B. That is +17.50% against the prior fiscal year, when revenue was $1.19B. The same year closed with net income of $177.69M. That is +1,168.11% against the prior fiscal year. Profit margin runs at 10.67%. That is 12.4 percentage points above the Medical Devices median of −1.69%. Trailing earnings per share are 4.09.

Across the 4 fiscal years on file, revenue moves from $847.13M in 2022 to $1.40B in 2025. Of those 4 years, 3 report positive net income.

Valuation Assessment

PEN trades at a trailing price-to-earnings ratio of 78.77. That is 193.92% above the Medical Devices median of 26.8. The forward P/E on file is 52.54. The PEG ratio, which sets the P/E against expected earnings growth, reads 3.62. Measured against sales, the shares trade at 8.43 times revenue. On price-to-sales that is 183.35% above the Medical Devices median of 2.98. The medians here are taken across 151 Medical Devices companies that report the metric.

Beta against the wider market is reported at 0.7. Annualized volatility over the trailing 10 years is 41.17%. Over the trailing twelve months the price has returned +15.18%. Measured over 10 years, that is +16.39% a year compounded.

Growth & Income

No dividend is on file for PEN.

The strongest complete calendar year on file is 2021 at +64.18%; the weakest is 2022 at −22.57%. Of the 9 complete calendar years on file, 7 finished higher. So far in 2026 the price is +3.62%.

Peer Comparison

Penumbra, Inc. (PEN) operates in the Medical Devices industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Penumbra, Inc. PEN $12.69B 78.8
Abbott Laboratories ABT $187.45B 35.1
Medtronic plc. MDT $120.46B 22.9
Stryker Corporation SYK $116.27B 31.9

The Medical Devices industry average P/E ratio is 26.8x. Penumbra, Inc. trades at a P/E of 78.8.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Medical Devices Stocks

ABT

Abbott Laboratories

$187.45B

 MDT

Medtronic plc.

$120.46B

 SYK

Stryker Corporation

$116.27B

 BSX

Boston Scientific Corporation

$69.27B

 EW

Edwards Lifesciences Corporation

$51.82B

 DXCM

DexCom, Inc.

$33.17B
View all Medical Devices stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Penumbra, Inc.

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, Access25; MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, aspiration pump, and other components and accessories under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that include the Penumbra Coil 400, for the treatment of aneurysms and other complex lesions, detachable coils of neurovascular lesions under the Penumbra SMART COIL, SwiftSET, and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, it provides peripheral embolization products, such as Ruby Embolization Platform, which consists of detachable coils for peripheral applications; Ruby LP and XL Embolization Platform; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; Packing Coil LP; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising the Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. It sells its products through direct sales organizations and distributors. The company was incorporated in 2004 and is based in Alameda, California.

Visit website →